News

Explore groundbreaking advancements in eye care from the 2000s, including LASIK innovations, anti-VEGF treatments, and enhanced imaging technologies.

DURAVYU is being developed as a potential sustained-delivery treatment for patients suffering from serious retinal diseases.

The VisiPlate aqueous shunt is made of a patented metamaterial that has been designed to be non-fibrotic and is many times thinner than a human hair, according to the company.

The approval follows the successful completion of a pivotal Investigational Device Exemption (IDE) study.

Andrew G. Lee, MD, and Drew Carey, MD, highlight how chronic lymphocytic leukemia can mimic Graves’ orbitopathy, underscoring the importance of a thorough evaluation.

Explore the groundbreaking advancements in ophthalmic technology from the 1980s and 1990s, including excimer lasers, LASIK, and innovative imaging techniques.

Attendees of the AAO 2025 annual meeting will have a chance to preview the virtual technician training platform on October 19, at 10:30 am in the Academy Theater, Hall WB1, Booth 2761.

The approval of the third-generation trifocal intraocular lens broadens the range of advanced lens options available for patients in the US.

From lasers to lenses, the 1970s redefined vision care through breakthroughs in surgery, imaging, and therapeutics.

The FDA describes the RDEA pilot program as a program to support novel endpoint efficacy development for drugs that treat rare diseases.

Emerging pharmacological and optical strategies are shaping a new era.

The Polaris platform is the world’s first AI-supported and robotics-enabled surgical system developed specifically for ophthalmology, according to the company.

EYDENZELT is Celltrion's first FDA-approved biologic product in ophthalmology.

Singh highlights how understanding the “why” behind diagnostics and procedures boosts technician confidence, fosters pride, and strengthens their role in patient care.

A recent study uncovers a novel biomarker for retinal vascular diseases, highlighting the significance of intermittent capillary perfusion in monitoring treatment efficacy.

The video-driven platform equips ophthalmic practices with tools to standardize education, improve workflow, and foster technician engagement.

Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).

Maximizing treatment based on GA location, lesion progression, and morphologic retinal changes.

A young surgeon reflects on training, technology, and the human side of adopting new excimer laser platforms.

Join the American Academy of Ophthalmology's annual meeting for cutting-edge insights, networking, and engaging events from October 17-20 in Orlando.

The company can now initiate the Opti-GAIN (Optimized Geographic Atrophy INterventional) phase 1/2 clinical trial.

Real-world insights emphasize identifying underlying causes to tailor treatment.

Both have issued further statements regarding the deal.

The procedure showed positive effects on the electroretinography (ERG) (b-wave, oscillatory potentials), optomotor response, and contrast sensitivity in actively treated eyes compared with controls.

A stepwise guide to optimize astigmatism management in cataract surgery

From early experiences in India to fellowship training at Wills Eye Hospital, Dr. Ansari discusses how ophthalmologists can make a lasting impact worldwide.

Learn how the YOURS Committee empowers young retina specialists through engaging educational initiatives, networking opportunities, and exam preparation resources.

Oculis plans to commence its PIONEER program, consisting of 3 trials, by the end of the year.